An Initiative for Speeding Innovation

2023
A Comprehensive Global Response to a Growing Threat

Our Focus on Driving Alzheimer’s Innovations

1. **Global Cohort Development**
   - Build a global cohort with high-quality, detailed data on a well-characterized, diverse population, readily available to researchers, to increase discovery of targets for drug development with associated biomarkers.

2. **Global Clinical Trials**
   - Reduce the cost and time to bring new treatments to market globally.

3. **Healthcare System Preparedness**
   - Facilitate the implementation of national, regional and global commitments to provide access to future innovations in treatment, diagnosis and care.
A Comprehensive Global Response

Our Approach to Speeding Innovation

1. Achieving Global Scale
2. Linking Regional and Sectoral Efforts
3. Engaging LMIC
Addressing Global Unmet Needs
A Track Record of Spurring Innovation

**Gavi**
Funds increased access to immunizations
$900M launch
$19B to date

**CEPI**
Funds vaccines research for emerging infectious diseases
$750M launch
$2B to date

**Davos Alzheimer’s Collaborative**
Funds innovation in Alzheimer’s disease
$750M goal at launch

2000 — 2021
Taking the Next Step to Respond to Global Commitments

2013
Ministers from each of the G7 countries committed to a 12-point plan to set an ambition goal to speed innovation.

2017
Set a global action plan at the World Health Assembly aimed at making a difference to the lives of people affected by dementia.

2019
G20 commits to promote healthy and active ageing and implement comprehensive set of policies to address dementia.

2020
Presentation during the 2020 Annual Meeting in Davos charges WEF and CEOi to develop a multi-year collaborative to change the pace of innovation in Alzheimer’s disease research and care.

2021
A $700+M collaboration announced
Link: http://www3.weforum.org/docs/WEF_The_Davos_Agenda_Overview_2021.pdf
A Comprehensive Global Response

Approximate Expense Budget for Programs

<table>
<thead>
<tr>
<th>Goal</th>
<th>Foundational Phase (2021-2022)</th>
<th>2023-2026</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Global Cohort Development</td>
<td>$10M</td>
<td>$355M</td>
<td>$365M</td>
</tr>
<tr>
<td>Build a global cohort with high-quality, detailed data on a well-characterized, diverse population to increase discovery of targets for drug development and identify associated biomarkers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Global Clinical Trials</td>
<td>$3M</td>
<td>$242M</td>
<td>$245M</td>
</tr>
<tr>
<td>Build a global platform and network to reduce the cost and time to bring new treatments to market globally</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Healthcare System Preparedness</td>
<td>$10M</td>
<td>$90M</td>
<td>$100M</td>
</tr>
<tr>
<td>Facilitate the implementation of global commitments to provide access to future innovations in treatment, diagnosis and care</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total: $710M
Global Cohort Development
Global Cohort Development Program

The Issues We Face

- Incomplete global understanding of the heterogeneity and the variability of Alzheimer’s etiology
- Need for new targets and biomarkers for drug development

Our Commitment

- Build a global cohort of 1 million people with high-quality, detailed data on a well-characterized, diverse population, readily available to researchers, to increase discovery of targets for drug development with associated biomarkers
Global Cohort Development Program

Select Accomplishments to Date

**Scale**

*Enrich Cohorts Around the World*

Secured participation from **23 cohorts representing over 130,000** people and partnership with **22+ cohorts** in a network in Europe and South America.

Completed trans-ethnic AD **Polygenic Risk Score** pilot.

**Diversity**

*Prioritize Low to Middle Income Countries*

Initiated digital phenotyping in **Malaysia and Argentina**.

**Broad Data Access**

*Decentralize Data Access*

Partnership with Gates Ventures’-funded **ADDI**.

**New Tools**

*Increase Data Collection Methods*

Reviewing potential leapfrog technologies (e.g., eye scanning, breath analysis, etc.).
The aging global population, which increases the number of families with Alzheimer’s, has a dramatic impact on national budgets, global economic growth and monetary policy.

Healthcare systems are not prepared to detect cognitive change, diagnose accurately, identify the right intervention or deliver future treatment.

Facilitate the implementation of national, regional and global commitments to provide access to future innovations in treatment, diagnosis and care.
# Patient Pathway

DAC Intends to Catalyze and Scale Innovation Across the Individual and Family Journey

## Prevention

- **Awareness and Activation**
  - Consumer Awareness & Activation
  - Public Awareness & Education
  - HCP Education & Activation

## Health Promotion

- **HCS Patient Flow**
  - Screening and early detection
  - Initial Focus
  - Diagnosis of MCI and dementia

## Integrated Healthcare

- **Long Term Care**
  - Care Planning
  - Healthcare Mgmt and Delivery
  - Dementia Care
  - Services and Social Support

## Access

- **Encourage Targeted Innovation**
Healthcare System Preparedness Program

Select Accomplishments to Date

Flagship Projects

Locally Driven Pilots

Communities of Practice

Learning Labs

Design and Implement Pilots

Crowdsourcing Innovation

Facilitate and Embed Change

Drive Adoption of Best Practices

7 pilots in 6 countries created – focused on disease detection.

Japan, Jamaica, UK, Mexico, Brazil and the US (2).

$4.5M RFP issued – focused on detection – which is funding 12 programs across the globe.

Monthly meetings held with flagship sites to share learnings and problem solve ultimately develop a durable tool kit for agile scaling.

Bi-annual meeting of governments and healthcare system executives initiated and metrics established to drive accountability.
Global Clinical Trials Support Platform
Clinical trials for Alzheimer’s disease therapies are long, slow and expensive – delaying getting treatments to patients and providing care for those impacted by the disease.

- Build and activate regional and global clinical trial networks and design advanced clinical trials that reduce the time, cost and improve the quality of AD clinical trials.

- Work with the other DAC initiatives to catalyze recruitment for clinical trials and development of reliable digital and blood biomarkers.
Clinical Trials Program

Select Accomplishments to Date

- GAP European Network
  - Design and Engage Sites
  - Scale w/Scottish NHS

- Transatlantic Trials
  - Design Transatlantic Trials with Sponsors
  - Secured 1 Therapeutic study and Biomarker study for use of NA/EUR Network

- ROW Trials
  - Mapping additional countries to add to CT Network
  - In discussions with Site Networks in Australia, China, Japan, Singapore, South Korea

30 sites committed

Currently negotiating MOU with Scottish NHS, Scottish memory clinics and Scottish/EUR trial network
Thank You

George Vradenburg
Vradenburg@aol.com
+1 202 414 0771

Drew Holzapfel
dholzapfel@highlanterngroup.com
+1 703 599 9617